達那唑
外觀
臨床資料 | |
---|---|
商品名 | Danatrol, Danocrine, Danol, Danoval, others |
其他名稱 | WIN-17757; 2,3-Isoxazolethisterone; 2,3-Isoxazol-17α-ethynyltestosterone; 17α-Ethynyl-17β-hydroxyandrost-4-en-[2,3-d]isoxazole |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682599 |
懷孕分級 |
|
給藥途徑 | 口服給藥 |
藥物類別 | 雄激素、同化類固醇、黃體製劑、孕激素、抗促性腺激素、固醇類合成抑制劑、抗動情素藥物 |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | Saturable with dosage, higher with food intake[1] |
血漿蛋白結合率 | 會與白蛋白、SHBG, CBG結合[2][3][4] |
藥物代謝 | 肝臟(CYP3A4)[8][5][9][1][6] |
代謝產物 | • 2-OHM-Ethisterone[5] • Ethisterone[6][7] |
生物半衰期 | Acute: 3–10 hours[8][1] Chronic: 24–26 hours[8] |
排泄途徑 | 尿、糞便[8][1] |
識別資訊 | |
| |
CAS號 | 17230-88-5 |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.037.503 |
化學資訊 | |
化學式 | C22H27NO2 |
摩爾質量 | 337.463 g/mol |
3D模型(JSmol) | |
| |
|
達那唑(Danazol)為一種用於治療子宮內膜異位症、乳腺小葉增生、遺傳性血管性水腫及其他疾病的藥物[8][1][10][11][12],主要經口服給藥[1]。
達那唑具有雄性化的副作用,使其用途大受限制。常見不良反應包含痤瘡、多毛症,以及聲音變低沉[1][13]。達那唑的作用機轉複雜,同時具有弱雄激素、弱同化類固醇、弱孕激素,弱抗促性腺激素、弱固醇類合成抑制劑,以及功能性抗動情素藥物[4][9][14][9][14][15]。
達那唑發現於1963年,並於1971年應用於醫學[9][16][17][18]。隨着副作用更少的性腺激素釋放素類似物應用逐漸廣泛,達那唑在治療子宮內膜異位症的角色已被前者所取代[3]。
參考文獻
[編輯]- ^ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 存档副本 (PDF). [2019-10-09]. (原始內容存檔 (PDF)於2021-04-02).
- ^ J.P. Griffin; P.F. D'Arcy. A Manual of Adverse Drug Interactions. Elsevier. 17 November 1997: 194– [2019-10-09]. ISBN 978-0-08-052583-9. (原始內容存檔於2021-08-28).
- ^ 3.0 3.1 Eberhard Nieschlag; Hermann M. Behre; Susan Nieschlag. Andrology: Male Reproductive Health and Dysfunction. Springer Science & Business Media. 13 January 2010: 426–428. ISBN 978-3-540-78355-8.
- ^ 4.0 4.1 Eric J. Thomas; John Rock. Modern Approaches to Endometriosis. Springer Science & Business Media. 6 December 2012: 239–256 [2019-10-09]. ISBN 978-94-011-3864-2. (原始內容存檔於2020-01-10).
- ^ 5.0 5.1 Thomas L. Lemke; David A. Williams. Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. 24 January 2012: 1361– [2019-10-09]. ISBN 978-1-60913-345-0. (原始內容存檔於2020-01-10).
- ^ 6.0 6.1 Florencio Zaragoza Dörwald. Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds. John Wiley & Sons. 4 February 2013: 485– [2019-10-09]. ISBN 978-3-527-64565-7. (原始內容存檔於2020-01-09).
- ^ Robert J. Kurman. Blaustein's Pathology of the Female Genital Tract. Springer Science & Business Media. 17 April 2013: 390– [2019-10-09]. ISBN 978-1-4757-3889-6. (原始內容存檔於2020-01-10).
- ^ 8.0 8.1 8.2 8.3 8.4 Brayfield, A (編). Danazol. Martindale: The Complete Drug Reference. Pharmaceutical Press. 30 October 2013 [1 April 2014]. (原始內容存檔於2021-08-28).
- ^ 9.0 9.1 9.2 9.3 Howard W. Jones; John A. Rock. Te Linde's Operative Gynecology. Wolters Kluwer Health. 10 July 2015: 1327–1330 [2019-10-09]. ISBN 978-1-4963-1521-2. (原始內容存檔於2020-01-10). 引用錯誤:帶有name屬性「JonesRock2015」的
<ref>
標籤用不同內容定義了多次 - ^ J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 345–. ISBN 978-1-4757-2085-3.
- ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000: 293– [2019-10-09]. ISBN 978-3-88763-075-1. (原始內容存檔於2020-01-10).
- ^ I.K. Morton; Judith M. Hall. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 6 December 2012: 91–. ISBN 978-94-011-4439-1.
- ^ Selak V, Farquhar C, Prentice A, Singla A. Farquhar C , 編. Danazol for pelvic pain associated with endometriosis. Cochrane Database of Systematic Reviews. 2007, (4): CD000068. PMID 17943735. doi:10.1002/14651858.CD000068.pub2.
- ^ 14.0 14.1 Aurel Lupulescu. Hormones and Vitamins in Cancer Treatment. CRC Press. 24 October 1990: 103– [2019-10-09]. ISBN 978-0-8493-5973-6. (原始內容存檔於2020-01-10).
- ^ Albert Altchek; Liane Deligdisch; Nathan Kase. Diagnosis and Management of Ovarian Disorders. Academic Press. 4 September 2003: 376– [2019-10-09]. ISBN 978-0-08-049451-7. (原始內容存檔於2020-01-09).
- ^ G.P. Ellis and G.B. Ellis, doi:10.1016/S0079-6468(08)70187-5 (1979), pp. 126, note 158, 130, notes 1513, 2369, citing doi:10.1021/jm00299a034
- ^ Alan N. Elias; Grant Gwinup. Hirsutism. Praeger. 1 January 1983: 70 [2019-10-09]. (原始內容存檔於2017-03-28).
- ^ Dmowski WP, Scholer HF, Mahesh VB, Greenblatt RB. Danazol--a synthetic steroid derivative with interesting physiologic properties. Fertil. Steril. 1971, 22 (1): 9–18. PMID 5538758. doi:10.1016/S0015-0282(16)37981-X.
延伸閱讀
[編輯]- Dmowski WP. Endocrine properties and clinical application of danazol. Fertil. Steril. March 1979, 31 (3): 237–51. PMID 374128. doi:10.1016/S0015-0282(16)43869-0.
- Fraser IS. Danazol--a steroid with a unique combination of actions. Scott Med J. April 1979, 24 (2): 147–50. PMID 386503. doi:10.1177/003693307902400209.
- Potts GO, Schane HP, Edelson J. Pharmacology and pharmacokinetics of danazol. Drugs. May 1980, 19 (5): 321–30. PMID 6993179. doi:10.2165/00003495-198019050-00001.
- Jenkin G. Review: The mechanism of action of danazol, a novel steroid derivative. Aust N Z J Obstet Gynaecol. May 1980, 20 (2): 113–8. PMID 6998453. doi:10.1111/j.1479-828X.1980.tb00107.x.
- Barbieri RL, Ryan KJ. Danazol: endocrine pharmacology and therapeutic applications. Am. J. Obstet. Gynecol. October 1981, 141 (4): 453–63. PMID 7025640. doi:10.1016/0002-9378(81)90611-6.
- Dmowski WP. Danazol. A synthetic steroid with diverse biologic effects. J Reprod Med. January 1990, 35 (1 Suppl): 69–74; discussion 74–5. PMID 2404115.
- Barbieri RL. Danazol: molecular, endocrine, and clinical pharmacology. Prog. Clin. Biol. Res. 1990, 323: 241–52. PMID 2406750.
- Hughes E, Brown J, Tiffin G, Vandekerckhove P. Danazol for unexplained subfertility. Cochrane Database Syst Rev. January 2007, (1): CD000069. PMID 17253444. doi:10.1002/14651858.CD000069.pub2.
- Beaumont H, Augood C, Duckitt K, Lethaby A. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev. July 2007, (3): CD001017. PMID 17636649. doi:10.1002/14651858.CD001017.pub2.
- Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. October 2007, (4): CD000068. PMID 17943735. doi:10.1002/14651858.CD000068.pub2.
- Craig TJ. Appraisal of danazol prophylaxis for hereditary angioedema. Allergy Asthma Proc. 2008, 29 (3): 225–31. PMID 18387221. doi:10.2500/aap.2008.29.3107.
- Ke LQ, Yang K, Li J, Li CM. Danazol for uterine fibroids. Cochrane Database Syst Rev. July 2009, (3): CD007692. PMID 19588442. doi:10.1002/14651858.CD007692.pub2.
- Letchumanan P, Thumboo J. Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review. Semin. Arthritis Rheum. February 2011, 40 (4): 298–306. PMID 20541792. doi:10.1016/j.semarthrit.2010.03.005.